Chemomab Therapeutics Ltd Quick Ratio (CMMB) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Chemomab Therapeutics Ltd   (NASDAQ: CMMB)

Chemomab Therapeutics Ltd 's Quick Ratio

CMMB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Chemomab Therapeutics Ltd 's Cash & cash equivalent, this led to improvement in Chemomab Therapeutics Ltd 's Quick Ratio to 12.61, above Chemomab Therapeutics Ltd average Quick Ratio.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Quick Ratio than Chemomab Therapeutics Ltd in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 339, from total ranking in the third quarter 2025 at 587.

Explain Quick Ratio?
How much Cash & cash equivalents CMMB´s has?
What are CMMB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMMB Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -69.63 % -52.37 % -71.47 % -52.37 % -31.28 %
Y / Y Cash & cash equivalent Change -27.34 % -27.34 % -26.42 % -27.34 % -27.89 %
Quick Ratio MRQ 12.61 7.01 8.97 7.01 5.27
CMMB's Total Ranking # 339 # 587 # # #
Seq. Current Liabilities Change -44.38 % 41.57 % -29.36 % -45.4 % -12.76 %
Seq. Cash & cash equivalent Change 0 % 10.69 % -9.66 % -27.34 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 120
Overall Market # 339


Quick Ratio Statistics
High Average Low
57.48 10.89 0.13
(Sep 30 2021)   (Dec 31 2018)




Financial Statements
Chemomab Therapeutics Ltd 's Current Liabilities $ 1 Millions Visit CMMB's Balance sheet
Chemomab Therapeutics Ltd 's Cash & cash equivalent $ 10 Millions Visit CMMB's Balance sheet
Source of CMMB's Sales Visit CMMB's Sales by Geography


Cumulative Chemomab Therapeutics Ltd 's Quick Ratio

CMMB's Quick Ratio for the trailling 12 Months

CMMB Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -61.64 % -51.41 % -46.12 % -34.27 % -33.59 %
Y / Y Cash & cash equivalent TTM Growth -27.13 % -27.33 % -27.49 % -35.81 % -43.84 %
Quick Ratio TTM 8.39 6.61 5.79 4.72 4.42
Total Ranking TTM # 2897 # 3442 # # #
Seq. Current Liabilities TTM Growth -28.1 % -19.5 % -23.89 % -12.93 % -8.92 %
Seq. Cash & cash equivalent TTM Growth -8.79 % -8.08 % -6.51 % -7.02 % -9.04 %

Quick ratio ranking by company, industry and sector >> Back to CMMB Financial Strength Comparisons >> Go to Compare CMMB Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Chemomab Therapeutics Ltd 's average Cash & cash equivalent, this led to increase in in Chemomab Therapeutics Ltd 's Quick Ratio to 8.39, Quick Ratio remained below CMMB average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 376 other companies have achieved higher Quick Ratio than Chemomab Therapeutics Ltd . While Quick Ratio overall ranking has improved so far to 2897, from total ranking during the twelve months ending third quarter 2025 at 3442.

Explain Quick Ratio?
How much Cash & cash equivalents CMMB´s has?
What are CMMB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 377
Healthcare Sector # 779
Within the Market # 2897


trailing twelve months Quick Ratio Statistics
High Average Low
25.09 8.5 0.34
(Mar 31 2022)   0




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Ligand Pharmaceuticals Incorporated  33.03 $ 1,236.811  Millions$ 37.447  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Disc Medicine Inc   32.19 $ 791.152  Millions$ 24.579  Millions
Fulcrum Therapeutics Inc   27.00 $ 352.306  Millions$ 13.048  Millions
Contineum Therapeutics Inc   26.98 $ 262.896  Millions$ 9.744  Millions
Rapport Therapeutics Inc   25.75 $ 490.539  Millions$ 19.049  Millions
Upstream Bio Inc   25.39 $ 341.509  Millions$ 13.452  Millions
Mbx Biosciences Inc   24.12 $ 373.705  Millions$ 15.495  Millions
Structure Therapeutics Inc   22.85 $ 1,446.197  Millions$ 63.285  Millions
Monopar Therapeutics Inc   22.61 $ 61.834  Millions$ 2.735  Millions
Kairos Pharma Ltd   22.57 $ 4.491  Millions$ 0.199  Millions
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions
Jade Biosciences Inc   20.33 $ 336.158  Millions$ 16.539  Millions
Siga Technologies Inc  19.99 $ 154.966  Millions$ 7.753  Millions
Trevi Therapeutics Inc   19.94 $ 188.260  Millions$ 9.442  Millions
Edgewise Therapeutics inc   19.37 $ 530.109  Millions$ 27.370  Millions
Maplight Therapeutics Inc   18.80 $ 305.103  Millions$ 16.229  Millions
Kezar Life Sciences Inc   16.92 $ 71.878  Millions$ 4.248  Millions
Stoke Therapeutics Inc   16.90 $ 284.670  Millions$ 16.840  Millions
Design Therapeutics Inc   16.84 $ 219.845  Millions$ 13.055  Millions
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions
Xbiotech Inc   15.83 $ 125.551  Millions$ 7.929  Millions
Tango Therapeutics Inc   15.83 $ 343.138  Millions$ 21.679  Millions
Mira Pharmaceuticals Inc   15.71 $ 11.030  Millions$ 0.702  Millions
Phio Pharmaceuticals Corp  15.69 $ 21.031  Millions$ 1.340  Millions
Alto Neuroscience Inc   15.58 $ 176.484  Millions$ 11.325  Millions

Date modified: 2026-07-07T10:09:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.